Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 270,000 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 270,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the completion of the sale, the chief executive officer owned 6,000 shares in the company, valued at approximately $361,980. This represents a 97.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ian Mortimer also recently made the following trade(s):

• On Tuesday, March 10th, Ian Mortimer sold 11,269 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total transaction of $677,379.59.
• On Friday, January 2nd, Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00.

Xenon Pharmaceuticals Stock Down 2.6%

XENE stock traded down $1.57 during midday trading on Wednesday, reaching $59.04. 5,546,191 shares of the company’s stock traded hands, compared to its average volume of 1,583,794. The company has a 50-day simple moving average of $43.23 and a two-hundred day simple moving average of $41.69. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $63.95. The company has a market cap of $4.91 billion, a price-to-earnings ratio of -13.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the prior year, the company posted ($0.84) earnings per share. Equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Hedge Funds Weigh In On Xenon Pharmaceuticals

Large investors have recently bought and sold shares of the business. Elevation Point Wealth Partners LLC acquired a new stake in Xenon Pharmaceuticals during the 2nd quarter worth $32,000. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares during the last quarter. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth $33,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter worth $39,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Robert W. Baird increased their price target on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Needham & Company LLC increased their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a research report on Monday. JPMorgan Chase & Co. lifted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Finally, Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $71.94.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.